TIDMAGL
RNS Number : 0306A
Angle PLC
24 September 2015
For immediate release 24 September 2015
ANGLE plc
("ANGLE" or "the Company")
PEER-REVIEWED PUBLICATION ON THE USE OF PARSORTIX SYSTEM WITH
PROSTATE CANCER PATIENTS
Potential for a simple blood test (liquid biopsy) for
personalised medicine in prostate cancer
ANGLE plc (AIM: AGL OTCQX: ANPCY), the specialist medtech
company, is pleased to announce that Barts Cancer Institute (BCI)
has published its work in prostate cancer patients using ANGLE's
Parsortix system in the PLOS ONE Journal a peer-reviewed,
open-access resource from the Public Library of Science.
The publication is available at
http://www.angleplc.com/the-parsortix-system/download-files/
Key findings in the publication are that:
-- Using the Parsortix system, BCI researchers were able to
successfully harvest cancer cells from 100% of the patients for
analysis.
-- The Parsortix system harvested a range of different
circulating cells comprising not only epithelial cells, which can
be captured by antibody-based systems, but also mesenchymal cells
and cell clusters.
-- The purity of the cells harvested by the Parsortix system was
three times higher than the best antibody-based system studied.
-- The cells harvested by the Parsortix system are clinically
relevant and offer the potential for the Parsortix system to be
used to provide a repeatable, non-invasive liquid biopsy for
prostate cancer patients.
-- The cells harvested by the Parsortix system are viable and it
is possible to culture the cells, growing the cancer outside the
patient.
-- Compared to traditional antibody-based systems, the Parsortix
system is quicker, easier to use, does not use expensive reagents,
captures a wider range of clinically relevant cells and avoids the
problems in downstream analysis caused by contaminating magnetic
beads.
-- Circulating tumour cells (CTCs) captured by the Parsortix
system hold much more genetic/molecular information than cell-free
DNA. Consequently CTC analysis has the potential to become the main
diagnostic tool for real-time personalised treatment in prostate
cancer.
Prostate cancer is the second most common cancer in men and the
fourth most common overall. More than 1.1 million cases of prostate
cancer were recorded in 2012, accounting for around 8 per cent of
all new cancer cases and 15 per cent in men (Source: World Cancer
Research Fund International).
Dr Yong-Jie Lu, Reader in Medical Oncology at Barts Cancer
Institute, commented:
"Understanding how molecular alterations in cancer cells change
and evolve during cancer progression and in response to
therapeutics is vital to better understanding cancer progression
and improving how we care for patients with metastatic disease. The
easy to use, epitope-independent Parsortix system not only captures
CTCs of all different phenotypes from cancer patients but it allows
their easy harvesting for downstream analysis. Furthermore the
cells are undamaged and we have shown them to be viable for cell
culture."
ANGLE Founder and Chief Executive, Andrew Newland,
commented:
"This is the first peer-reviewed publication in a scientific
journal in relation to the clinical use of ANGLE's Parsortix
system. It adds to the growing body of published evidence of the
system's performance as a liquid biopsy in a range of cancers
including ovarian, prostate and breast cancers. The prospect of
deployment of our repeatable, non-invasive liquid biopsy in the
treatment of prostate cancer patients is exciting."
For further information:
ANGLE plc 01483 685830
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
Cenkos Securities
Stephen Keys, Dr Christopher Golden
(Nominated adviser)
Russell Kerr, Olly Baxendale (Sales) 020 7397 8900
FTI Consulting
Simon Conway, Mo Noonan, Stephanie
Cuthbert 020 3727 1000
Kimberley Ha (US) 001 212 850 5612
For Frequently Used Terms, please see the Company's website on
http://www.angleplc.com/the-parsortix-system/glossary/
Notes for editors
About ANGLE plc www.angleplc.com
ANGLE is a specialist medtech company commercialising a
disruptive platform technology that can capture cells circulating
in blood, such as cancer cells, even when they are as rare in
number as one cell in one billion blood cells, and harvest the
cells for analysis.
ANGLE's cell separation technology is called the Parsortix
system and it enables a liquid biopsy (simple blood test) to be
used to provide the cells of interest. Parsortix is the subject of
granted patents in the United States, China and Australia and three
extensive families of patents are being progressed worldwide. The
system is based on a microfluidic device that captures cells based
on a combination of their size and compressibility. The Parsortix
system is established with strong positive evaluations from leading
cancer research centres and is working with these cancer centres to
demonstrate key applications. Parsortix has a CE Mark for Europe
and FDA authorisation is in process for the United States.
The analysis of the cells that can be harvested from patient
blood with ANGLE's Parsortix system has the potential to help
deliver personalised cancer care offering profound improvements in
clinical and health economic outcomes in the treatment and
diagnosis of various forms of cancer.
The global increase in cancer to a 1 in 3 lifetime incidence is
set to drive a multi $billion clinical market. The Parsortix system
is designed to be compatible with existing major medtech analytical
platforms and to act as a companion diagnostic for major pharma in
helping to identify patients that will benefit from a particular
drug and then monitoring the drug's effectiveness.
Now that the Parsortix system has been developed, ANGLE is
focused on its commercialisation in the market.
ANGLE is strongly focused on establishing the use of the
Parsortix system in clinical practice. To achieve this, ANGLE has
established formal collaborations with world-class cancer centres.
These key opinion leaders are working to identify applications with
medical utility (clear benefit to patients), and to secure clinical
data that demonstrates that utility in patient studies. ANGLE
believes this is the optimal approach for unlocking the
multi-billion dollar worldwide market available to the Company and
its potential strategic partners. Details are available here
http://www.angleplc.com/the-company/collaborators/
As well as cancer, the Parsortix technology has the potential
for deployment with several other important cell types in the
future.
ANGLE began trading on the AIM market of the London Stock
Exchange in March 2004 under the ticker symbol AGL. For further
information please visit: www.angleplc.com.
About Barts Cancer Institute http://www.bci.qmul.ac.uk/about-us
Barts Cancer Institute is part of the Barts Cancer Research UK
Centre of Excellence and one of the top five cancer research
centres in the UK.
Barts Cancer Institute, within the Barts and the London School
of Medicine and Dentistry, was recently placed in the top ten
medical schools in the UK and world-wide.
Located in the Centre of London in Charterhouse Square - 1 of 3
Queen Mary University of London campuses - over 40 research groups
across Barts Cancer Institute's six specialist Centres create
world-class outputs in research, clinical trials and teaching.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCPGUAABUPAPUW
(END) Dow Jones Newswires
September 24, 2015 02:01 ET (06:01 GMT)
Angle (LSE:AGL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Angle (LSE:AGL)
Historical Stock Chart
From Apr 2023 to Apr 2024
